Skip to content

Clinical study of secukinumab in the treatment of chronic sinusitis with nasal polyps

Clinical study of secukinumab in the treatment of chronic sinusitis with nasal polyps

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119197
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis with Nasal Polyps

Interventions

A group(Subcutaneous injection of drugs):None
C group(Surgery + Medication):None
B group(Surgery):None

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old, gender not limited. 2. Meet the above diagnostic criteria for chronic sinusitis with nasal polyps. 3. The patient signed the informed consent form, voluntarily participated in this study, and was willing to abide by the requirements of the study protocol, cooperating to complete all examinations and follow-ups. 4. Be capable of understanding and correctly completing relevant scoring scales (such as NCS score, SNOT-22 score, etc.).

Exclusion criteria

Exclusion criteria: 1.Those who are allergic to secukinumab or its excipients. 2. There are serious underlying diseases that may affect the research results or patient safety, such as severe cardiovascular diseases (such as uncontrolled hypertension, unstable angina pectoris, myocardial infarction, etc.), liver and kidney dysfunction, hematological diseases, and neurological diseases. 3. Within the past three months, other biological agents have been used to treat chronic sinusitis with nasal polyps or other type 2 inflammation-related diseases. 4. Within the past month, systemic glucocorticoids (excluding the maintenance dose of inhaled glucocorticoids), immunosuppressants and other drugs that may affect the efficacy and safety assessment of the study drug have been used. 5. Those who suffer from mental illness and are unable to cooperate in completing research or signing the informed consent form. 6. Pregnant or lactating women. 7. Other circumstances where the researcher deems it unsuitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Nasal Congestion Score,NCS;

Secondary

MeasureTime frame
Sino-Nasal Outcome Test-22;Visual Analogue Scale,VAS;Lund-Kennedy score of nasal endoscopy;Lund-Mackay score of paranasal sinus CT;Nasal Polyp Score,NPS;Evaluation of olfactory function;

Countries

China

Contacts

Public ContactShaoqing Yu

Shanghai Tongji Hospital

yu_shaoqing@163.com+86 21 66111042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026